Syneos Health Inc

Syneos Health — Jefferies Virtual Healthcare Conference 2020

19 slides from Syneos Health's conference presentation, Jun 3, 2020

  1. Slide 1: Jefferies Virtual Healthcare Conference

    Exhibit 99.1 Jefferies Virtual Healthcare Conference Alistair Macdonald Chief Executive Officer June 3, 2020

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Measures

    Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this EBITDA, adjusted EBITDA, and adjusted EBITDA margin. We also include in this presentation non-GAAP presentat

  3. Slide 3: Market Leader Purpose-Built for Biopharmaceutical Acceleration

    Market Leader Purpose-Built for Biopharmaceutical Acceleration Clinical Solutions TOP % of 3 74% CRO TTM # 1 Adjusted CCO Only Revenue 26% end-to-end biopharma Commercial Solutions product development organization in the world >$75B >90% combined market of FDA approved Novel Syneos One™ opportunity

  4. Slide 4: Purpose-Built to Address Unique Clinical Development Needs

    Purpose-Built to Address Unique Clinical Development Needs Flexibility to Improve the Likelihood of Regulatory and Commercial Success Differentiators Uniquely Support Market Segmentation Early Phase Scientific Affairs & Reporting Proof of Concept Catalyst Translational Sciences Site Network Geograph

  5. Slide 5: Expanding Clinical Share Positions for Continued Growth

    Expanding Clinical Share Positions for Continued Growth Share Strength and Opportunity 3 Strategic wins with Top 30 Pharma since Q1 18 <5% ~15% Strong position with 21 - 50 Market ~10% Market where flexibility matters Share Market Share Share Top 20 Pharma 21 - 50 Pharma SMID CRO Market Outsourced C

  6. Slide 6: Building Momentum with Large Pharma

    Building Momentum with Large Pharma Preferred Provider Wins with Top 30 Pharma Demonstrate the Strength of our Unique Capabilities … you won this work because you understand our goals and vision, the combination of your clinical and “commercial capabilities, and the fact that you consider patients a

  7. Slide 7: Commercial Industry Leader Positioned for the Modern Market

    Commercial Industry Leader Positioned for the Modern Market Unparalleled Breadth of Capabilities Uniquely Positioned for a Dynamic Market Deployment Solutions Field-Based Promotional Solutions and Clinical Teams Strategy Design Recruiting 61% Sales Operations Market >15% Growth 2 Engagement Center L

  8. Slide 8: Syneos One: Unique End-to-End Integrated Product Development Offering

    Syneos One™: Unique End-to-End Integrated Product Development Offering Driving Awards and Pipeline Differentiated product offering in the market $1.4B $475M+ Improves speed to market through integrated early planning, design and execution estimated potential of TTM Clinical and Focused on maximizing

  9. Slide 9: COVID-19 Response and Mitigating Actions

    COVID-19 Response and Mitigating Actions % of TTM Mitigating Revenue Actions Full-Service 60% • On track to convert 70 – 80% of Q2 visits to Clinical Remote Monitoring • Working non-Site Activities in SSU • Remote Monitoring of existing patients • Recruitment in less affected regions COVID-19 Public

  10. Slide 10: Focus on Margin Enhancement Drives Shareholder Value

    Focus on Margin Enhancement Drives Shareholder Value Targeting 13 – 14% FY 2020 Adjusted EBITDA margin1 and 30 – 50 bps of margin expansion in 2021 COVID-19 Cost Management & Liquidity Preservation Actions • Accelerated ForwardBound margin enhancement initiative • Implemented temporary cost actions

  11. Slide 11: Balanced Approach to Capital Deployment

    Balanced Approach to Capital Deployment Successfully Managing our Capital Structure and Related Costs Debt Reduction Tuck-in Acquisitions Share and Management and Strategic Partnerships Repurchases Redeemed 7.5% Senior Notes in Q4 2019 Continue to review tuck-in acquisition and Board approved extens

  12. Slide 12: Q2 2020 Outlook

    Q2 2020 Outlook $M (except margin, growth rate, and per share data) Guidance Range Growth Rate Revenue1,2 $ 1,000 - $ 1,020 (14.4) % – (12.7) % Adjusted EBITDA $ 107 - $ 117 (30.4) % – (23.9) % Adjusted EBITDA Margin3 10.7% - 11.5% Adjusted Diluted EPS $ 0.48 - $0.52 (35.1) % – (29.7) % Note: Financ

  13. Slide 13: Investment Summary: Driving Shareholder Value

    Investment Summary: Driving Shareholder Value Comprehensive Fit-for-Purpose Unique Syneos One™ Product Development Insights across Clinical product offering solutions and Commercial $ $ $ Increasing share and Value creation Balanced momentum via capital deployment with Margin Enhancement Large Pharm

  14. Slide 14: Shortening the Distance From Lab to Life

    Shortening the Distance From Lab to Life®.

  15. Slide 15: Appendix

    Appendix 15

  16. Slide 16: Q2 2020 Guidance Reconciliation: Adjusted Net Income and Adjusted Diluted EPS

    Q2 2020 Guidance Reconciliation Adjusted Net Income and Adjusted Diluted EPS Adjusted Net Income Adjusted Diluted Earnings Per Share $M (except per share data) Low High Low High GAAP Net Loss and Diluted Loss per Share $ (6.3) $ (3.5) $ (0.06) $ (0.03) Adjustments: Amortization1 39.0 39.0 0.37 0.37

  17. Slide 17: Q2 2020 Guidance Reconciliation: Adjusted EBITDA

    Q2 2020 Guidance Reconciliation Adjusted EBITDA $M Low High GAAP Net Loss $ (6.3) $ (3.5) Adjustments: Interest Expense, Net1 23.0 25.0 Income Tax Expense1 (2.7) (1.5) Depreciation1 18.0 20.0 Amortization1 39.0 39.0 EBITDA 71.0 79.0 Restructuring and Other Costs1 15.0 15.0 Transaction Expenses1 4.0

  18. Slide 18: Reconciliation of GAAP Revenue by Segment to Adjusted Revenue by Segment

    Reconciliation of GAAP Revenue by Segment to Adjusted Revenue by Segment $M Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Clinical Solutions revenue, as reported $ 783.9 $ 819.2 $ 821.2 $ 805.0 $ 849.9 $ 867.4 $ 899.3 $ 874.8 Clinical Solutions deferred revenue adjustment (a) 3.4 2.9 2.9 1.6 1.6 1

  19. Slide 19: Shortening the Distance From Lab to Life

    Shortening the Distance From Lab to Life®.

Syneos Health — Jefferies Virtual Healthcare Conference 2020 on 6ix